Should biologics for psoriasis be interrupted in the era of COVID-19?
作者： Mark Lebwohl , Ryan Rivera-Oyola , Dedee F. Murrell
DOI: 10.1016/J.JAAD.2020.03.031
关键词: Betacoronavirus 、 Pandemic 、 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 、 Virology 、 Psoriasis 、 MEDLINE 、 Pneumonia 、 Coronavirus disease 2019 (COVID-19) 、 Medicine 、 2019-20 coronavirus outbreak
摘要: In Table I, we compare overall infection rates as well as rates of upper respiratory infections and nasopharyngitis for each drug versus its placebo control based on published data from …
jaad.org
sci-hub.se 参考文章(4)
K. Reich, J.-P. Ortonne, A.B. Gottlieb, I.J. Terpstra, G. Coteur, C. Tasset, P. Mease, Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension British Journal of Dermatology. ,vol. 167, pp. 180- 190 ,(2012) , 10.1111/J.1365-2133.2012.10941.X
J‐P Ortonne, A Taieb, AD Ormerod, D Robertson, J Foehl, R Pedersen, C Molta, B Freundlich, Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. British Journal of Dermatology. ,vol. 161, pp. 1190- 1195 ,(2009) , 10.1111/J.1365-2133.2009.09238.X
Katrina Gee, Christina Guzzo, Nor Che Mat, Wei Ma, Ashok Kumar, The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflammation and Allergy - Drug Targets. ,vol. 8, pp. 40- 52 ,(2009) , 10.2174/187152809787582507
A. Blauvelt, K.A. Papp, H. Sofen, M. Augustin, G. Yosipovitch, N. Katoh, U. Mrowietz, M. Ohtsuki, Y. Poulin, D. Shrom, R. Burge, K. See, L. Mallbris, K.B. Gordon, Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis Journal of the European Academy of Dermatology and Venereology. ,vol. 31, pp. 1004- 1013 ,(2017) , 10.1111/JDV.14163